Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 06, 2021 08:00 ET | Source: Surrozen, Inc.

Surrozen Strengthens Board of Directors with Appointments of Mace Rothenberg, M.D., and Christopher Chai

SOUTH SAN FRANCISCO, Calif., May 06, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today...
March 11, 2021 14:37 ET | Source: Surrozen, Inc.

Surrozen Expands Board of Directors with Appointment of Mary Haak-Frendscho, Ph.D.

SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today...
February 02, 2021 18:31 ET | Source: Surrozen, Inc.

Surrozen Expands Board of Directors with Appointment of Shao-Lee Lin, M.D., Ph.D.

SOUTH SAN FRANCISCO, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today...
November 12, 2020 07:00 ET | Source: Surrozen, Inc.

Surrozen to Present at the Stifel 2020 Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced that Craig Parker,...
October 29, 2020 07:00 ET | Source: Surrozen, Inc.

Surrozen Appoints Charles Williams as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced the appointment of...
October 15, 2020 07:00 ET | Source: Surrozen, Inc.

Surrozen Awarded NIH Grant to Support Development of SZN-043, a Liver-Specific Regenerative Antibody, for the Treatment of Severe Alcoholic Hepatitis

SOUTH SAN FRANCISCO, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, has been awarded an NIH grant to...
September 25, 2020 07:00 ET | Source: Surrozen, Inc.

Surrozen Expands Board of Directors with Appointment of David J. Woodhouse, Ph.D.

SOUTH SAN FRANCISCO, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced the addition of...
September 16, 2020 07:00 ET | Source: Surrozen, Inc.

Surrozen to Present at Morgan Stanley 18th Annual Global Healthcare Conference

-- Craig Parker, CEO of Surrozen, to present Surrozen’s advancements in regenerative medicine -- SOUTH SAN FRANCISCO, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology...
August 19, 2020 10:00 ET | Source: Surrozen, Inc.

Surrozen Announces Publication of Second Antibody Platform Technology in Scientific Reports

-- Novel approach to creating R-spondin-mimetics establishes proof-of-concept for targeted regenerative antibodies -- SOUTH SAN FRANCISCO, Calif., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc.,...
June 19, 2020 10:00 ET | Source: Surrozen, Inc.

UPDATE -- Surrozen Raises $50 Million in Series C Financing to Advance Candidates to Human Clinical Trials

SOUTH SAN FRANCISCO, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced the successful...